Literature DB >> 18554967

Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome.

Tzuping Wei1, Ilya Sabsovich, Tian-Zhi Guo, Xiaoyou Shi, Rong Zhao, Wenwu Li, Christian Geis, Claudia Sommer, Wade S Kingery, David J Clark.   

Abstract

BACKGROUND: Tibia fracture in rats evokes chronic hindpaw warmth, edema, allodynia, and regional osteopenia, a syndrome resembling complex regional pain syndrome (CRPS). Previous studies suggest that the pathogenesis of some of these changes involves an exaggerated regional inflammatory response to injury and we postulated that inflammatory cytokines contribute to the development of CRPS-like changes after fracture.
METHODS: The distal tibia was fractured and the hindlimb casted for 4 weeks. The rats were given drinking water with or without the cytokine inhibitor pentoxifylline (PTX) starting the day before fracture and continuing for 4 weeks, after which time the cast was removed and multiple assays were performed in the hindpaw. PCR and immunoassays were used to evaluate changes in cytokine expression. Bilateral hindpaw thickness, temperature, and nociceptive thresholds were determined, and bone microarchitecture was measured by microcomputed tomography (microCT).
RESULTS: Tibia fracture chronically up-regulated TNFalpha, IL-1beta and IL-6 mRNA and protein levels in hindpaw skin and PTX treatment significantly reduced the mRNA expression and cytokine protein levels for all these cytokines. PTX inhibited the nociceptive sensitization and some vascular changes, but had insignificant effects on most of the bone-related parameters measured in these studies. Immunostaining of hindpaw skin was negative for immunocyte infiltration at 4 weeks post-fracture.
CONCLUSIONS: These results suggest that pro-inflammatory cytokines contribute to the nociceptive and vascular sequelae of fracture and that PTX treatment can reverse these CRPS-like changes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18554967      PMCID: PMC2673487          DOI: 10.1016/j.ejpain.2008.04.014

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  63 in total

Review 1.  The role of nuclear factor-kappa B in cytokine gene regulation.

Authors:  T S Blackwell; J W Christman
Journal:  Am J Respir Cell Mol Biol       Date:  1997-07       Impact factor: 6.914

2.  Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha.

Authors:  C J Woolf; A Allchorne; B Safieh-Garabedian; S Poole
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

3.  The effect of pentoxifiline on post-injury hyperalgesia in rats and postoperative pain in patients.

Authors:  J Wordliczek; A M Szczepanik; M Banach; J Turchan; M Zembala; M Siedlar; R Przewlocki; W Serednicki; B Przewlocka
Journal:  Life Sci       Date:  2000-02-11       Impact factor: 5.037

4.  Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models.

Authors:  Y Waki; T Horita; K Miyamoto; K Ohya; S Kasugai
Journal:  Jpn J Pharmacol       Date:  1999-04

5.  Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints.

Authors:  Carlos R Tonussi; Sérgio H Ferreira
Journal:  Pain       Date:  1999-07       Impact factor: 6.961

6.  Transmission of chronic nociception by spinal neurons expressing the substance P receptor.

Authors:  M L Nichols; B J Allen; S D Rogers; J R Ghilardi; P Honore; N M Luger; M P Finke; J Li; D A Lappi; D A Simone; P W Mantyh
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

7.  Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription.

Authors:  G C Parry; N Mackman
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

8.  Association of TNFA gene polymorphism at position -308 with susceptibility to irritant contact dermatitis.

Authors:  M H Allen; S H Wakelin; D Holloway; S Lisby; O Baadsgaard; J N Barker; J P McFadden
Journal:  Immunogenetics       Date:  2000-03       Impact factor: 2.846

9.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  Nitrous oxide produces antinociceptive response via alpha2B and/or alpha2C adrenoceptor subtypes in mice.

Authors:  T Z Guo; M F Davies; W S Kingery; A J Patterson; L E Limbird; M Maze
Journal:  Anesthesiology       Date:  1999-02       Impact factor: 7.892

View more
  31 in total

Review 1.  The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs.

Authors:  Haroon Hameed; Mariam Hameed; Paul J Christo
Journal:  Curr Pain Headache Rep       Date:  2010-04

2.  Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction.

Authors:  Maarten Albersen; Thomas M Fandel; Haiyang Zhang; Lia Banie; Guiting Lin; Dirk De Ridder; Ching-Shwun Lin; Tom F Lue
Journal:  Eur Urol       Date:  2010-10-26       Impact factor: 20.096

3.  Bisphosphonates Inhibit Pain, Bone Loss, and Inflammation in a Rat Tibia Fracture Model of Complex Regional Pain Syndrome.

Authors:  Liping Wang; Tian-Zhi Guo; Saiyun Hou; Tzuping Wei; Wen-Wu Li; Xiaoyou Shi; J David Clark; Wade S Kingery
Journal:  Anesth Analg       Date:  2016-10       Impact factor: 5.108

Review 4.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

5.  Immobilization contributes to exaggerated neuropeptide signaling, inflammatory changes, and nociceptive sensitization after fracture in rats.

Authors:  Tian-Zhi Guo; Tzuping Wei; Wen-Wu Li; Xiang-Qi Li; J David Clark; Wade S Kingery
Journal:  J Pain       Date:  2014-07-22       Impact factor: 5.820

6.  Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome.

Authors:  Wen-Wu Li; Tian-Zhi Guo; De-yong Liang; Yuan Sun; Wade S Kingery; J David Clark
Journal:  Anesthesiology       Date:  2012-04       Impact factor: 7.892

7.  Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture.

Authors:  W-W Li; T-Z Guo; X Shi; Y Sun; T Wei; D J Clark; W S Kingery
Journal:  Neuroscience       Date:  2015-09-16       Impact factor: 3.590

8.  Activation of cutaneous immune responses in complex regional pain syndrome.

Authors:  Frank Birklein; Peter D Drummond; Wenwu Li; Tanja Schlereth; Nahid Albrecht; Philip M Finch; Linda F Dawson; J David Clark; Wade S Kingery
Journal:  J Pain       Date:  2014-01-23       Impact factor: 5.820

9.  Epidermal adrenergic signaling contributes to inflammation and pain sensitization in a rat model of complex regional pain syndrome.

Authors:  Wenwu Li; Xiaoyou Shi; Liping Wang; Tianzhi Guo; Tzuping Wei; Kejun Cheng; Kenner C Rice; Wade S Kingery; J David Clark
Journal:  Pain       Date:  2013-04-12       Impact factor: 6.961

10.  Optimizing postoperative sexual function after radical prostatectomy.

Authors:  Manuela Tutolo; Alberto Briganti; Nazareno Suardi; Andrea Gallina; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Niccolò Passoni; Alessandro Nini; Nicola Fossati; Patrizio Rigatti; Francesco Montorsi
Journal:  Ther Adv Urol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.